could go up to £2.00 per share From The Mail Online : Shares of the AIM-listed healthcare firm, which is sitting on two potentially explosive products in the sexual enhancement field, rose 2.5p to 101p on hot gossip that Reckitt Benckiser and Australia’s Ansell are both willing to pay up to £2 a share to gain full control of the Surrey-based company. They would love to get their hands on Futura’s most exciting new prospect
"PET500 will be marketed as part of Ansell's LifeStyles® brand and it is expected that it will be launched from July in a phased roll-out throughout the USA. We expect recurring royalty income to begin to flow this year but as the launch is phased the initial royalties are likely to be relatively modest."
I joined Futura after more than 35 years at GlaxoSmithKline, most recently as the President of its Consumer Healthcare division. My executive career has given me considerable experience of the consumer healthcare sector, which I believe is reliant on one thing: innovation. Futura is a company with innovation at its core. It also has a great team of people, which it is a privilege for me to join. Its DermaSys® delivery system is at the forefront of transdermal drug delivery, a delivery route that is particularly appealing for OTC products. DermaSys® creates the opportunity for Futura to develop organically into a substantial business. It is my intention to help Futura realise the full potential of its market opportunities whilst also using my experience of global companies to assist in its licensing strategy. 2012 promises to be a very exciting year for Futura with two products close to launch and a pipeline of further opportunities at various stages of development. I look forward to contributing to the Company's success.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.